Basel-Vanagaite-Smirin-Yosef syndrome (OMIM 616449) is a rare autosomal recessive genetic disorder characterized by severe developmental delay and variable craniofacial, neurological, cardiac, and ocular anomalies in the presence of variants in the MED25 gene. So far, only a handful of patients have been reported with this condition globally. Here, we report an additional Lebanese family with 2 affected siblings presenting with severely delayed psychomotor and language development as well as craniofacial anomalies. By whole-exome sequencing (WES), a homozygous variant was found in the MED25 gene, c.518T>C, predicted to result in a p.Ile173Thr change in the MED25 protein. This change has recently been reported in another Lebanese family. Review of the literature, the importance of this mutation in the Lebanese population, and the possibility that this condition may be underdiagnosed and only effectively detected using molecular techniques such as WES are discussed.

Keywords:
Autosomal recessive disorder, Lebanon, MED25, Mutation
1.
Abouelhoda M, Sobahy T, El-Kalioby M, Patel N, Shamseldin H, et al. Clinical genomics can facilitate countrywide estimation of autosomal recessive disease burden. Genet Med 18:1244-1249 (2016).
2.
Alkuraya FS: Discovery of rare homozygous mutations from studies of consanguineous pedigrees. Curr Protoc Hum Genet Chapter 6:Unit6.12 (2012).
3.
Basel-Vanagaite L, Smirin-Yosef P, Essakow JL, Tzur S, Lagovsky I, et al: Homozygous MED25 mutation implicated in eye-intellectual disability syndrome. Hum Genet 134:577-587 (2015).
4.
Figueiredo T, Melo US, Pessoa AL, Nobrega PR, Kitajima JP, et al: Homozygous missense mutation in MED25 segregates with syndromic intellectual disability in a large consanguineous family. J Med Genet 52:123-127 (2015).
5.
Nair P, Lama M, El-Hayek S, Abou Sleymane G, Stora S, et al: COQ8A and MED25 mutations in a child with intellectual disability, microcephaly, seizures, and spastic ataxia: synergistic effect of digenic variants? Mol Sydromol 9:319-323 (2018).
6.
Romdhane L, Kefi R, Azaiez H, Ben Halim N, Dellagi K, Abdelhak S: Founder mutations in Tunisia: implications for diagnosis in North Africa and Middle East. Orphanet J Rare Dis 7:52 (2012).
7.
Tadmouri GO, Nair P, Obeid T, Al Ali MT, Al Khaja N, Hamamy HA: Consanguinity and reproductive health among Arabs. Reprod Health 6:17 (2009).
8.
Zlotogora J, Hujerat Y, Barges S, Shalev SA, Chakravarti A: The fate of 12 recessive mutations in a single village. Ann Hum Genet 71:202-208 (2007).
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.